Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • jkersh
    Member
    • Apr 2010
    • 11

    Looking for opinions on stopping HiSeq 2000 service contract

    Hello everyone,

    We currently have an older HiSeq 2000 housed in our facility (V3 runs only) that isn't currently getting much use because of the low cost of V4 runs. We are considering taking it off the service contract and running it for relatively low cost 1x50 runs. Has anyone had any experience running one without a service contract, or used a different vendor that is lower cost? Our biggest issue with this instrument is that it is so expensive to maintain!

    Thanks!
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    Someone else may have more practical advice to share but here goes ..

    If you do find a lower cost provider they will ultimately need to go to illumina for (proprietary) parts (if/when needed). This could put your facility lower on the list of "priority" with Illumina. Illumina would also be less inclined to offer replacement reagents if something goes wrong with a run and you don't have a maintenance contract with them (I don't think third party providers cover reagent replacements). You will want to weigh how much money you expect to save and the business you may lose if the instrument stays down for a month. Perhaps you can try to negotiate a lower cost/level support contract with your local illumina sales rep.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    29 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    21 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    211 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    78 views
    0 reactions
    Last Post SEQadmin2  
    Working...